Cancers & treatments·Regimen libraryFirst line

Bendamustine + rituximab (BR)

Checked 2026-09-09

Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable

One cycle

every 28 days × 6 · about 24 weeks in total

28-day cycle × 6 (about 24 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Bendamustine Alkylating agent (nitrogen mustard-purine hybrid)	90 mg/m² (70 mg/m² in CLL combinations)	IV	D1, 2
Rituximab Monoclonal antibody (anti-CD20, chimeric)	375 mg/m²	IV	D1

Cycles

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Prolonged lymphopenia: PJP and herpes prophylaxis; avoid BR immediately before CAR-T collection.

Used in

Follicular lymphoma Mantle cell lymphoma Chronic lymphocytic leukaemia Waldenström macroglobulinaemia

Products

BendamustineRituximab

Source

StiL NHL1, Lancet 2013

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.